Previous studies show that human myeloma-derived cell lines specifically adhere to fibronectin (FN) through very late antigen-4 (VLA-4; a"@, integrin complex) and RGDpeptide mechanisms, which may contribute to the localization of tumor cells in bone marrow (BM). In these studies, we characterized the adhesion of myeloma-derived cell lines to both normal and myeloma BM stromal cells (BMSCs) and the effect of adhesion on DNA synthesis. Because interleukin-6 (IL-6) plays an important role in the pathogenesis of multiple myeloma, we also examined the effects of tumor cell adhesion on IL-6 secretion by BMSCs. In 51chromium binding assays, the U266, ARH-77, and IM-9 cell lines showed 52% f 12%, 55% 2 6%. and 47% f 7% specific adherence, respectively, to normal BMSCs and 74% f 4%. 60% f 3%. and 61% f 6% specific adherence, respectively, to myeloma BMSCs. 
tan, and IM-9 cells, respectively (n = 5, P < .01). In contrast, adherence of IL-6-dependent B9 cells increased their proliferation (stimulation index, 3.2 f 0.7). Significant (twofold to eightfold) increases in IL-6 secretion were evident in cell line-adherent (212 hours) normal and myeloma BMSC cultures. Paraformaldehyde fixation of BMSCs before adhesion completely abrogated IL-6 secretion, suggesting that IL-6 secretion was triggered in BMSCs rather than in cell lines. Partial blocking of cell line adhesion to BMSCs, using anti-81 integrin and anti-82 integrin MoAbs and RGD peptide, also partially blocked the triggering of IL-6 secretion by BMSCs. When cell lines were placed in Transwell inserts and then cultured with either normal or myeloma BMSCs, permitting juxtaposition without cell to cell contact between myeloma cell lines and BMSCs, no increase in IL-6 secretion was observed. These studies suggest that adhesion to BMSCs may not only localize tumor cells in marrow but also permit cell-tocell contact and facilitate stimulation of IL-6 secretion by BMSCs in a paracrine growth mechanism. BM to receive the signals leading to proliferation, terminal differentiation, and production of osteoclast-activating factors. Ahsmann et als have reported that the lymphocyte function-associated antigen-1 (LFA-1 ) expression on plasma cells correlates with tumor cell labeling index, suggesting an involvement of this adhesion molecule in cellular interactions resulting in plasma cell proliferation. Finally, preliminary studies have shown that neoplastic plasma cells express cell surface molecules associated with lymphocyte recirculation and adhesion' and suggest that myeloma cells cannot bind to rat high endothelial venules (HEV), consistent with their lack of migration into PB." In contrast, plasma cell leukemia cells do adhere to rat HEV, facilitating their exit into the circulation. All of these studies confirm a role for adhesion molecules in localization of myeloma cells to marrow, but the functional significance of adhesion in the pathophysiology of myeloma is not yet defined.
Interleukin-6 (IL-6) is a growth factor for murine plasmacytoma cells, human myeloma cells, and myeloma cell lines.'',12 Plasmacytomas can be induced in mice by intraperitoneal injection of paraffin oil or pristane, which are potent inducers of IL-6 biosynthe~isl~; in addition, massive plasmacytosis can be generated in transgenic mice carrying the IL-6 genomic gene fused to the Ig heavy chain enhancer.I4 Previous studies in our15-17 and laboratories have suggested that IL-6 may mediate growth of myeloma cells either in an autocrine or paracrine fashion. In myeloma cells, IL-1 21 and granulocyte-macrophage colonystimulating factor (GM-CSF)" have been reported to augment and IL-426,27 to inhibit IL-6-mediated tumor cell growth. IL-6 is produced by activated monocytes, T cells, B cells, fibroblasts, endothelial cells, as well as normal and myeloma BMSCs and myeloma-derived cell For example, Kittler et a16 have reported that murine Dexter stromal cells constitutively produce IL-6, as well as other growth factors, and that exposure of stromal cells to either IL-1 or pokeweed mitogen induces IL-6 expression. Such growth factor production may support granulocyte, macrophage, and megakaryocyte production and stem cell maintenance in Dexter-type long-term murine BM cultures. Similar studies of regulation of IL-6 in myeloma BMSCs may define its role in the growth of myeloma in a paracnne growth mechanism.
In the present study, we attempted to determine the pattern and functional significance of adherence of myelomaderived cell lines to normal and myeloma BMSCs. The U266, ARH-77, and IM-9 cell lines showed specific adherence to normal and myeloma BMSCs. This binding could be partially blocked by preincubation and culture of cell lines with anti-P 1 integnn monoclonal antibody (MoAb), anti-P2 integrin MoAb, and excess RGD peptide to block binding to FN. Binding of these cell lines to FN and myeloma BMSCs resulted in no significant change in proliferation; however, binding of IL-6-dependent B9 cells to normal BMSCs stimulated their DNA synthesis. Importantly, IL-6 secretion by BMSCs was significantly increased after adherence of cell lines to either normal or myeloma BMSCs, an effect that requires cell line to BMSC contact. These studies suggest that adhesion to BMSCs may not only localize tumor cells in marrow, but also permit cell-to-cell contact and facilitate stimulation of IL-6 secretion by BMSCs in a paracrine growth mechanism. 
MATERIALS AND METHODS
Cell lines. The U266, HS-Sultan, IM-9, and ARH-77 human myeloma-derived cell lines, as well as the HL60 promyelocytic leukemia, U937 myelomonocytic leukemia, and Raji and Ramos Burkitt's lymphoma cell lines were obtained from the American Type Culture Collection (Rockville, MD). Cells were cultured in RPMI 1640 containing 10% to 15% fetal bovine serum (FBS), 100 U/mL penicillin (Pen), and 100 pg/mL streptomycin (Strep) (GIBCO, Grand Island, NY).
BMSC cultures. BM specimens were obtained from patients with MM and from normal volunteers. Mononuclear cells (MNCs) separated by Ficoll-Hypaque density sedimentation were used to establish long-term BM cultures according to the method described by Gartner and Kaplan," with a slight modification. MNCs were suspended in 10 mL of growth medium containing Iscove's modified Dulbecco's medium (IMDM), 20% fetal calf serum (FCS), Pen (100 U/mL), and Strep (100 pg/mL) in 25-cm2 flasks. Cells were incubated at 37°C in a C 0 2 incubator. After 2 weeks of incubation, cells were washed and fresh medium containing 20% FCS, Pen (100 U/mL), Strep (100 pg/mL), and epidermal growth factor (4 ng/mL) added every 3 to 4 days to augment the growth of BMSCs. When an adherent cell monolayer had developed, the cells were harvested in Hanks' Buffered Saline Solution (HBSS) containing 0.25% trypsin and 0.02% EDTA, washed, and collected by centrifugation. The confluent adherent BMSCs showed predominantly fibroblast morphology.
Assays of adhesion of myeloma cell lines to FN and to normal or myeloma BMSCs. Assays for adhesion of myeloma cell lines to FN were performed as previously de~cribed.~ Human plasma FN was obtained from Collaborative Research, Inc (Lexington, MA) and suspended at 0.04 mg/mL in RPMI-1640 media. Ninety-sixwell microtiter plates (Nunc, Roskilde, Denmark) were coated with 20 pL of FN, air-dried, and washed with I% bovine serum albumin (BSA; Sigma Chemicals, St Louis, MO) in RPMI-1640 media. Nonspecific binding was blocked by incubation with 10 mg/mL heatdenatured BSA in phosphate-buffered saline (PBS) for 1 hour at 37°C. Control wells were coated with heat-denatured BSA only.
Assays for adhesion of myeloma cell lines to normal and myeloma BMSCs were performed as previously described," with a slight modification. Myeloma cell lines were labeled with 51Cr (1 pCi/mL) in saline for 1 hour. Cells were then washed twice with HBSS and resuspended at 5 X 105/mL in medium containing RPMI-1640 and 1 % BSA (Sigma). One hundred microliters of labeled cells was added to each well of a 96-well microtiter plate (Nunc) containing a BMSC monolayer (2 X IO4 BMSCs per well) that had been previously incubated for 24 hours in medium. After incubation at 37°C for 30 minutes, the nonadherent cells were removed by inverted centrifugation (90g for 5 minutes). Remaining bound cells were lysed with 0.1% NP-40 in distilled water, and the radioactivity in cell lysates analyzed using a gamma counter (Packard Instrument Co, Downers Grove, IL).
To characterize the mechanism of binding of myeloma cell lines to BMSCs, blocking agents were used. Our previous studies showed the expression of VLA-4 ((31 integrin) and LFA-1 (p2 integrin) on these myeloma cell lines and the blocking of their specific adherence to FN using anti-pl integrin MoAbs and RGD peptide? Each cell line was therefore preincubated and cultured with anti-(31 integrin (4B4) MoAb Ninety-six-well microtiter plates (Nunc) were coated with FN, as described above.4 After 24 hours of incubation with myeloma cell lines ( 5 X IO4 cells/well) at 37"C, the supernatants were collected and their IL-6 bioactivity measured. Similarly, trypsinized normal or myeloma BMSCs were suspended in 96-well plates (2 X IO4 cells/200 pL/well). After BMSCs formed a confluent adherent layer, wells were washed five times with HBSS. Myeloma cell lines ( 5 X IO4 cells/100 pL) were added to each well. In some experiments, BMSCs in 96-well plates were fixed with 1% paraformaldehyde in PBS before the addition of myeloma cell lines. After incubation at 37°C for 24 hours, the supernatants were collected and their IL-6 bioactivity measured.
Suspended normal or myeloma BMSCs were also added to 24-well plates (lo5 cells/mL/well). After a confluent monolayer had formed, myeloma cell lines (2.5 X IO5 cells/mL/well) were either directly added to BMSCs or placed in Transwell-inserts (Costar, Cambridge, MA),33 which were then added to BMSCs. Transwellinserts separated myeloma cells from the BMSCs by a 0.45-pm microporous membjane, allowing free passage of diffusible factors but preventing myeloma cell lines from cell-to-cell contact with and adhesion to BMSCs. After 24 hours of incubation at 37"C, the levels of IL-6 in the supernatants were measured using the B9 bioassay.
DNA synthesis was measured, as previously described," with and without adhesion of myeloma cell 
IL-6 bioassay.

RESULTS
Characrerization ofadhe.sion of human myeloma-derived cell lines to BMSCs. The myeloma cell lines were evaluated for their adhesion to normal as well as myeloma BMSCs. As can be seen in Fig 1, the U266, ARH-77, and IM-9 cell lines showed 52% f 12%, 55% f 6%, and 47% fi 7% specific adherence, respectively, to normal BMSCs. These lines also adhered specifically to myeloma BMSCs: 74% fi 4% for U266 cells, 60% f 3% for ARH-77 cells, and 61% f 6% for IM-9 cells. In contrast, only 12% to 13% specific adherence of HS-Sultan cells was noted to either normal or myeloma BMSCs. Thus, there seems to be no difference in pattern of adhesion ofthese cell lines to normal and myeloma BMSCs. Next, we examined adhesion of other cell lines to normal BMSCs. As can be seen in Fig 2,  HL60 promyelocytic leukemia, U937 myelomonocytic leukemia, and Raji Burkitt's lymphoma-derived cells showed only 8.6% f 0.6%, 6.4% f 1.2% and 5.6% f 2.2% specific adherence to BMSCs, respectively; however, Ramos Burkitt's lymphoma and B9 IL-6-dependent hybridoma cells showed 34.8% fi 3.8% and 18.9% fi 4.1% specific adherence to normal BMSCs, respectively. Therefore, adherence to BMSCs is not specific for myeloma cell lines. Ramos cell line was used as a control in further experiments, because it strongly adhered to BMSCs.
To define the mechanism of binding of cell lines to BMSCs, attempts were made to block adherence ofcell lines to BMSCs by both preincubation and coculture of cell lines with the anti-4B4 (CD29) MoAb (which neutralizes 81 integrin-related binding), the 10F12 (CD18) MoAb (which blocks 82 integrin related binding), and with excess RGD peptide (which blocks binding to FN). As can be seen in Fig  3, binding of ARH-77 cells to normal BMSCs in the presence of anti-81 (4B4) MoAb. anti-02 (IOF12) MoAb, and excess RGD peptide was reduced by 19% f 3% (n = 9, P < .Ol), 1 8 % f 5 % ( n = 9 , P < . O I ) , a n d 1 6 % + 5 % ( n = 9 , P < .05), respectively, relative to binding in the presence of media or media including irrelevant Ig-matched MoAb (anti-CD3) as a negative control. The adhesion of IM-9 cells to normal BMSCs was also decreased by culture with anti-82 integrin (10F12) MoAb (23% 2 7%; n = 9, P < .Ol) and RGD peptide (22% f 6%: n = 9, P < .Ol) compared with Fig 2) ; adherence also decreased DNA synthesis of these cells (SI of 0.1 f 0.02; Fig 4) . suggesting that this effect was not unique to myeloma cell lines. To determine whether the decrease in cell proliferation after adhesion to normal BMSCs is caused by a soluble factor, we examined the effect of BMSC conditioned media on cell proliferation (Table I) . Specifically, supernatants collected at 24 hours from 96-well plates of confluent BMSCs did not alter DNA synthesis of myeloma cell lines. Although adhesion of IM-9 cells to myeloma BMSCs increased cell proliferation in some experiments, this effect was neither reproducible nor statistically significant (SI of 1.8 f 0.9; n = 5; P > .05).
Moreover, there was no significant change in DNA synthesis after adhesion of U266, ARH-77, or HS-Sultan myeloma cell lines to myeloma BMSCs (Fig 5 ) or to FN (data not shown).
Because the above-mentioned myeloma cell lines are not IL-6 dependent, we examined DNA synthesis of the IL-6-dependent B9 cells with or without adhesion to normal BMSCs. Twenty percent specific adherence of B9 cells to normal BMSCs was noted (Fig 2) ; moreover, DNA synthesis was increased up to threefold after adherence of B9 cells to normal BMSCs (n = 3: Fig 4) .
Effect of myeloma cell line adherence on IL-6 secretion by normal BMSCs. The B9 bioassay was used to assay IL-6 concentration in the supernatants at I, 6, 12, 24, and 48 hours of culture of normal BMSCs with media alone or with myeloma cell lines. As can be seen in Fig 6, IL-6 was readily detectable at 1 hour in cultures of BMSCs in media alone (80 pg/mL) and increased gradually by 24 hours (>60 ng/ mL). Moreover, the adhesion of U266 and IM-9 cell lines increased IL-6 secretion by normal BMSCs 1.8-and 3.4-fold, respectively, after 24 hours of culture. After paraformaldehyde fixation of BMSCs, specific adhesion of tumor cells without associated IL-6 secretion was noted (n = 4), suggesting that adhesion triggers IL-6 secretion by BMSCs rather than tumor cell lines.
Because stimulation of IL-6 secretion by adherence of U266 and IM-9 cells to normal BMSCs was maximal at 24 hours of culture, we chose to measure IL-6 in culture supernatants at this interval in subsequent experiments. Both normal and myeloma BMSCs produced 15 ng/mL to 1,343 ng/mL of IL-6 (Table 2 ). There was no significant difference 
3[H]TdR uptake of BMSCs in media)/'[H]TdR uptake of cell lines in media.
For (Table 2 ). For example, binding of the ARH-77 cell line increased IL-6 secretion 2.7-f 0.5-fold (n = 6, P < .05) and 3.5-f I. I-fold (n = 6, P < .05) by normal and myeloma BMSCs, respectively. Binding of IM-9 cells triggered a 2.3-f 0.4-fold (n = 6, P < .05) and 2.4-& 0.5-fold (n = 6, P < .05) increment in IL-6 secretion by normal and myeloma BMSCs. respectively. Adherence ofthe HS-Sultan cell line led to a 1.6-f 0.2-fold (n = 6, P < .05) increase in IL-6 secretion by myeloma BMSCs, without triggering IL-6 secretion by normal BMSCs (1.6-f 0.5-fold, n = 6, P > .05). Adherence of U266 cells significantly increased IL-6 secretion by myeloma BMSCs ( 1.6-f 0.3-fold, n = 6, P < .05), without affecting IL-6 secretion by normal BMSCs (1.3-f 0.2-fold. n = 6, P > .05). IL-6 secretion by normal BMSCs was also increased fourfold by the adhesion of Ramos cells, suggesting that this effect is not specific for myeloma cell lines. an Ig identical unreactive control and did not alter the IL-6 secretion triggered by adherence of myeloma cell lines to normal BMSCs.
e[]i>ct ($blocking
To confirm the requirement for cell-to-cell contact and adhesion of cell lines for triggering IL-6 secretion by BMSCs. we used Transwell-inserts, which completely block cell line to BMSC contact and adhesion. Myeloma cell lines were placed in Transwell-inserts and then cultured with either normal or myeloma BMSCs, thereby permitting juxtaposition without cell to cell contact between the myeloma cell lines and BMSCs. As can be seen in Table 3 , adherence of the ARH-77 (n = 6, P < .05) and IM-9 (n = 6, P < .05) cell lines triggered a significant increase in the secretion of IL-6 by normal BMSCs. Adherence of ARH-77 (n = 6, P < .05), U266 (n = 6, P < .05), HS-Sultan (n = 6, P < .05), and IM-9 (n = 6, P < .05) cell lines also significantly increased IL-6 secretion by myeloma BMSCs. However, when these myeloma cell lines were placed in Transwell-inserts and For personal use only. on August 30, 2017. by guest www.bloodjournal.org From then incubated with BMSCs, no increments in IL-6 secretion were demonstrable (Table 3) . Thus, cell to cell contact and adhesion of tumor cells to BMSCs appears to be necessary to trigger IL-6 secretion by BMSCs.
DISCUSS ION
MM is a clonal malignancy spanning the pre-B to plasma cell stages of B-cell differentiation. Although pre-B cells and idiotype-bearing lymphocytes may circulate in PB,'-3 malignant plasma cells are localized primarily in the BM and circulate in the PB only rarely, except in late stages with plasma cell leukemia. However, little is known ofthe mechanisms by which malignant plasma cells adhere to BMSCs and how these usually sessile cells unexpectedly appear in the blood. Because the marrow is the primary microenvironment for malignant plasma cells, it is important to define the interaction between malignant plasma cells, extracellular matrix proteins, and BMSCs that may facilitate both tumor cell localization and their growth. Members of the integrin family of cell adhesion receptors mediate both cell to extracellular matrix and cell to cell adhesion and are involved in cell migration and localization. We have previously reported that human myeloma-derived cell lines specifically adhered to FN, and that this binding was mediated by VLA-4-and RGD-peptide-dependent mechanism^.^ This process, coupled with the lack of tumor cell binding to collagen type IV and laminin that could mediate binding to the basal lamina and thereby mediate their exit from marrow to the vascular space,4 may contribute to tumor cells remaining within marrow. Because the primary human BM stromal monolayer in culture is a complex mixture of several different cell types, including fibroblasts, endothelial cells, and macrophages, multiple adhesion pathways may play an important role in cell to cell adhesion, ie, ICAMILFA-1 as well as VCAM-l/VLA-4 interactions. We and others have reported that myeloma cell lines expressed LFA-1 (CD 1 1 a/CD 1 8) and VLA-4,438 and Teixido et a134 reported that BMSCs expressed both ICAM-I and VCAM-I constitutively; myeloma cell to BMSC interaction may therefore be mediated by these adhesion molecules.
In the present report, we compared the adhesion pattern of myeloma cell lines with that ofeither normal or myeloma BMSCs. There is no significant difference of the adhesion patterns of tumor cells to either normal or myeloma BMSCs. Adherence of myeloma cell lines to BMSCs was partially blocked with anti-PI integrin MoAb and anti-P2 integrin MoAb, suggesting that PI integrins, ie, VLA-4/ VCAM-1 interaction, and P2 integrins, ie, LFA-I/ICAM-1 or 2, mediating cell-to-ECM and cell-to-cell contact, respectively, may play a role in the binding of myeloma cell lines to BMSCs. Partial blocking of cell line adhesion by excess RGD peptide confirms the previously observed binding to FN. 4 Moreover, the observation that combinations of these blocking agents failed to completely block the adhesion of myeloma cell lines to normal BMSCs suggests that other ligand-receptor pairs may also mediate the binding to BMSCs, ie, CD4435 or ~y n d e c a n ,~~ and that blocking ofbinding via one ligand-receptor pair may be compensated by binding mediated via an alternative mechanism. We and others have also reported the presence of other molecules concerned with lymphocyte recirculation and intercellular adhesion (CD44 and CD54) on myeloma cell^.^.^ Similar interactions have also been reported for other B-cell malignancies, ie, binding and localization of follicular non-Hodgkin's lymphoma cells to neoplastic lymph node follicles mediated by VLA-4 on the tumor cell and VCAM-I on follicular dendritic cells,37 and may be critical in the trafficking of tumor cells within marrow and lymphoid tissues.
Of even greater importance is the functional sequelae of adherence of tumor cells to extracellular matrix proteins and BMSCs. Caligaris-Cappio et a17323 have suggested that circulating clonogenic cells may selectively home to the BM to receive the signals leading to proliferation, terminal differentiation, and production of osteoclast-activating factors. Ahsmann et al* have reported that LFA-1 expression on myeloma cells correlates with their labeling indices, suggesting that adherence may augment their proliferation. In our studies, specific binding of myeloma cell lines to FN or myeloma BMSCs did not appear to have functional sequelae, because tumor cell proliferation was unaffected. Previous reports that adhesion to BMSCs may augment tumor cell p r~l i f e r a t i o n~.~~~~ are in contrast to the lack of similar effects obkerved in the present studies. Our findings may be related to the short incubation time of tumor cells with BMSCs to achieve optimal specific adherence and assessment of the effect of adhesion on cell proliferation. This discrepancy may be also explained by differences between freshly isolated tumor cells and non-IL-6-dependent myeloma-derived cell lines. These lines proliferate spontaneously in media only, and data from our and other laboratories suggest that either exogenous IL-6 or neutralizing antibody to IL-6 has only minor, if any, effects on their g r~w t h . '~,~~,~~ However, adherence of the B9 IL-6-dependent cells to normal BMSCs increased their DNA synthesis, suggesting that proliferation of myeloma cells may occur related to the IL-6 produced by BMSCs. Future studies using freshly isolated myeloma cells and IL-6-dependent human myeloma derived-cell lines will be needed to clarify the effect of adhesion to BMSCs on tumor cell proliferation.
IL-6 is a growth factor for murine plasmacytoma cells, human myeloma cells, and myeloma cell lines either in an autocrine or paracrine mechanism."s25 However, whether normal BM secretes IL-6 in the absence of stimulation remains controversial. Caligaris-Cappio et a17 have reported that myeloma BMSCs are in a state of activation and differ from normal BMSCs, which produce IL-6 only after activation with inflammatory mediators. However, Cuba et aI3' reported that normal marrow stromal fibroblasts secrete IL-6 even in the absence of inflammatory stimulators, and that normal human serum has an enhancing effect on IL-6 production by stromal fibroblasts. In our study, we could not detect a significant difference in the IL-6 secretion by normal and myeloma BMSCs. Our experiments were performed in media containing 20% FBS, which may have triggered IL-6 production by BMSCs. Nonetheless, in the present study, adherence of myeloma cell lines to either normal or myeloma BMSCs markedly augmented IL-6 secretion, suggesting that the adhesion process induces IL-6
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From signal transduction, analogous to the role of adhesion molecules inducing growth factor synthesis in other systems. In our previous r e~o r t ,~ we showed that IL-6 treatment decreased the binding of IM-9 cells to FN. Thus, adhesion of tumor cells to BMSCs may induce IL-6, which may in turn decrease tumor cell binding, thereby regulating IL-6 kinetics in the marrow microenvironment. As described before, IL-6 upregulation in BMSCs by adhesion was not specific for myeloma cells; however, B9 cell proliferation after adhesion suggests that IL-6-responsive myeloma cells may use IL-6 induced by adhesion. This is analogous to recent reports of the induction of IL-7 production by ST2 stromal cells by coculture with IL-7-dependent B cells. 39 Experiments to date suggest that cell-to-cell contact is necessary for stimulation of IL-6 by BMSCs. In particular, Caligaris-Cappio et al' have reported that plasma cells derived from myeloma patients grew tightly adherent to the stromal cell layer, and that their expansion was matched by a sharp increase of IL-6. In our studies, we determined the level of IL-6 in the supernatants after adding myeloma cell lines to normal or myeloma BMSCs. Culture of BMSCs with myeloma cell lines stimulated the IL-6 production by BM stromal cells at 24 hours. No IL-6 was measured in the supernatants when myeloma cell lines were cultured with paraformaldehyde-fixed BMSCs, suggesting that IL-6 secretion induced by tumor cell adhesion was secreted by BMSCs, and not induced in the tumor cell lines. To determine the role of adhesion in stimulating IL-6 secretion, we used Transwell-insert chambers,33 which allow juxtaposition but prevent cell-to-cell contact between myeloma cell lines and BMSCs. The increase in IL-6 induced by adherence of cell lines to BMSCs was completely abrogated when cell lines were placed in Transwell-inserts, confirming that the adhesion process plays a critical role in the stimulation of IL-6 production by BMSCs. As noted previously, the binding of these myeloma cell lines to BMSCs is partially mediated by (31 integrin, (32 integrin, and RGD-dependent mechanisms. However, attempts to block binding of cell lines with MoAbs directed against (31 and (32 integrins as well as excess RGD peptide only partially blocked adhesion and only partially inhibited the associated triggering of IL-6 secretion by BMSCs. Further experiments are needed to define additional adhesion molecule(s) that may be mediating adhesion and triggering IL-6 signal transduction in BMSCs, perhaps by cross-linking with 81 or (32 integrins and RGD-peptide-dependent mechanisms.
Members of the 61 and 82 integrin families of adhesion molecules are known to be involved in signalling proce~ses.~' For example, LFA-I is involved in the mobilization of intracellular Ca2+ and synergizes with CD3 in the induction of T-cell proliferation and tyrosine phosphorylation of cellular proteins in ~i t r o .~' -~~ Interaction of the (31 integrin VLA-4 with FN, or with marrow in long-term culture, may induce terminal normal B-cell differentiation and concomitant lg secretion.44 Therefore, it is possible that transmembrane signalling through adhesion receptors might be involved in pathogenesis of myeloma. Future studies in our laboratory will further delineate mechanisms of adherence of tumor cells to extracellular matrix proteins and to BMSCs and, in particular, use reporter assays with IL-6 promoter fragments linked to chloramphenicol acetyltransferase gene (CAT reporter assays)29 to characterize the mechanisms of IL-6 induction in BMSCs triggered by tumor cell adhesion.
